Key Highlights
- Kåre Schultz brings extensive leadership experience in healthcare.
- Schultz’s tenure includes roles at Teva Pharmaceutical, Lundbeck, and Novo Nordisk.
- Andrew Dudum, CEO of Hims & Hers, highlights Schultz’s transformative impact.
- Schultz joins a diverse and experienced Board of Directors.
Source: Business Wire
Notable Quotes
- “We are in a transformative moment for healthcare with the opportunity to make life-changing treatments accessible to all who need it. Kåre’s experience gives us an incredible wealth of expertise as we bring together the most valuable elements of clinical excellence, healthcare, and technology to redefine health and wellness for our customers.” — Andrew Dudum, CEO and Co-founder at Hims & Hers
- “Hims & Hers is on a trajectory to upend the healthcare industry. In my long career in the pharmaceutical industry, this is the first company I have seen that is leveraging today’s modern tools to truly break down barriers and change the status quo of how people access the health solutions they need to live their fullest lives. I’m thrilled to be a part of this journey.” — Kåre Schultz, appointed to the Board of Directors at Hims & Hers
SoHC's Take
The appointment of Kåre Schultz to the Hims & Hers Board of Directors marks a significant milestone for the company. Schultz’s extensive background in the pharmaceutical industry, particularly his leadership roles at Teva Pharmaceutical, Lundbeck, and Novo Nordisk, brings invaluable expertise to Hims & Hers. His strategic vision and ability to streamline operations will be instrumental as the company continues to innovate and expand its platform. This move underscores Hims & Hers’ commitment to revolutionizing healthcare by integrating clinical excellence with advanced technology, ultimately making health and wellness more accessible to a broader audience.
